CEACAM5 ADC-ANTI-PD1/PD-L1 COMBINATION THERAPY

Abstract: provided are methods for combination treatment of a cancer using an antibody-drug conjugate (adc) targeting ceacam5 and an anti-pd-1 antibody or anti-pd-l1 antibody, optionally together with a platinum-containing agent such as cisplatin or carboplatin with or without pemetrexed. in certain embodiments the adc is tusamitamab ravtansine. in certain embodiments the anti-pd-1 antibody is pembrolizumab. in certain embodiments, the cancer is nonsquamous non-small cell lung cancer (nsq nsclc). in certain embodiments, the cancer is advanced or metastatic nsq nsclc.

Inventor(s): Mustapha CHADJAA, Nathalie LE BAIL, Christine SOUFFLET, Phillip DENNIS, Samira BENSFIA

CPC Classification: C07K16/2803 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250154250